This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (39)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Aggressive Resection vs Chemotherapy

J. Christian Jensen, MD; Harvey I. Pass, MD; William F. Sindelar, MD; Jeffrey A. Norton, MD

Arch Surg. 1991;126(4):457-461.

Abstract
• In a retrospective, nonrandomized comparison of patients with first recurrence of adrenocortical cancer, 18 patients were treated with chemotherapy (primarily mitotane) and 15 patients were treated with surgical resection plus similar chemotherapy. Surgical resection of recurrent adrenocortical cancer was often extensive, with morbidity in 20% of patients and no mortality. Mitotane therapy was ineffective at controlling tumor growth. Median survival from the time of diagnosis for all patients was only 23 months and no patient was cured. Disease-free interval greater than 12 months was associated with prolonged survival, but it only occurred in six patients (18%), with a similar frequency in both treatment groups. Surgical resection of recurrent disease was associated with prolonged survival from the time of first recurrence. The potential benefit of this resection was evident in the 5 patients (33%) who were able to live greater than 5 years from the time of first recurrence with improvement in symptoms and signs of hypercortisolism. Although no patient with recurrent adrenal cancer could be cured, resection of recurrent disease was associated with a slight prolongation of survival and good palliation of Cushing's syndrome.

(Arch Surg. 1991;126:457-461)

Author Affiliations
From the Surgical Metabolism Section and the Thoracic Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Md.

Footnotes
Accepted for publication November 19, 1990.

Read before the 43rd Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, May 21, 1990.

Reprint requests to Surgical Metabolism Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bldg 10, Room 2B07, Bethesda, MD 20892 (Dr Norton).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adrenocortical Carcinoma: Clinical Update
Allolio and Fassnacht
J. Clin. Endocrinol. Metab. 2006;91:2027-2037.
ABSTRACT | FULL TEXT  

Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart et al.
Endocr Relat Cancer 2005;12:667-680.
ABSTRACT | FULL TEXT  

Radiofrequency Ablation of Metastatic Lesions in Adrenocortical Cancer
Abraham et al.
ANN INTERN MED 2000;133:312-313.
FULL TEXT